ReviewBiomedicines2025

Employing an Artificial Intelligence Platform to Enhance Treatment Responses to GLP-1 Agonists by Utilizing Metabolic Variability Signatures Based on the Constrained Disorder Principle.

Jakob Landau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.